Trial Intelligence Report - TS-5887

Protocol Summary

Indication:	General
Phase:	Follow-up Days -28 to -1 Baseline Day 0 Wk 1 Day 7 Wk 4 Day 28 Wk 8 Day 56 W
Sample Size:	108
Duration (weeks):	24
Dropout Rate:	7.9%
Primary Endpoint:	Frequency of moderate to severe adverse events through Week 24 by dosing level, freq

Success Prediction

62.1%

Assessment: Moderate probability of success

Strategic Recommendations

1. Consider increasing sample size if feasible.

2. Implement robust retention strategies to reduce dropout.

3. Review endpoint selection and measurement timing.